Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
about
Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsAnti-idiotype antibodies in cancer treatment.Immunological and histopathological changes in sheep affected with cutaneous squamous cell carcinoma and treated immunotherapeutically.New Approaches in Immunotherapy for the Treatment of Lung Cancer.
P2860
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
@ast
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
@en
type
label
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
@ast
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
@en
prefLabel
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
@ast
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
@en
P2860
P356
P1476
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.
@en
P2093
Maria L Ardigo
Roberto E Gómez
P2860
P356
10.3389/FONC.2012.00147
P577
2012-10-29T00:00:00Z